GlaxoSmithKline (GB:GSK) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline (GSK) has settled two lawsuits related to its heartburn medication, Zantac, without admitting liability, ending legal disputes with plaintiffs John Russell and Annette Hughes over cancer claims. Despite ongoing litigation, GSK stands by the scientific consensus that there is no substantial evidence linking ranitidine, the active ingredient in Zantac, to an increased risk of cancer. The company remains committed to defending its interests and protecting shareholders in the face of these allegations.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.